Acute Management of Hypercalcemia

The Parathyroids: Basic and Clinical Concepts: Third Edition

Volumn , Issue , 2015, Pages 617-629

  Minisola, Salvatore ^a   Romagnoli, Elisabetta ^a   Carnevale, Vincenzo ^b   Scillitani, Alfredo ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

Author keywords

Bisphosphonates; Calcitonin; Corticosteroids; Fluid replacement; Gallium nitrate; Hypercalcemia; Malignancy; Management; Parathyroid crisis; Pathophysiology

Indexed keywords

EID: 84936933830     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-397166-1.00042-4     Document Type: Chapter

References (109)

1. Fraser W.D. Hyperparathyroidism. Lancet 2009, 374:145-158.
2. Pepe J., Cipriani C., Pilotto R., De Lucia F., Castro C., Lenge L., et al. Sporadic and hereditary primary hyperparathyroidism. J Endocrinol Invest 2011, 34(7Suppl):40-44.
3. Siilin H., Lundgren E., Mallmin H., Mellström D., Ohlsson C., Karlsson M., et al. Prevalence of primary hyperparathyroidism and impact on bone mineral density in elderly men: MrOs Sweden. World J Surg 2011, 35:1266-1272.
4. Lindner G., Felber R., Schwarz C., Marti G., Leichtle A.B., Fiedler G.M., et al. Hypercalcemia in the ED: prevalence, etiology, and outcome. Am J Emerg Med 2013, 31:657-660.
5. Potts J.T., Jüppner H. Disorders of the parathyroid gland and calcium homeostasis. Harrison's Principle of Internal Medicine 2012, 3096-3120. McGraw-Hill Companies, Inc, New York. 18th ed. D.L. Longo, A.S. Fauci, D.L. Kasper, S.L. Hauser, J.L. Jameson, J. Loscalzo (Eds.).
6. Minisola S., Romagnoli E., Scarnecchia L., Pacitti M.T., Rosso R., Carnevale V., et al. Parathyroid storm: immediate recognition and pathophysiological considerations. Bone 1993, 14:703-706.
7. Starker L.F., Björklund P., Theoharis C., Long W.D., Carling T., Udelsman R. Clinical and histopathological characteristics of hyperparathyroidism-induced hypercalcemic crisis. World J Surg 2011, 35:331-335.
8. Picolos M.K., Lavis V.R., Orlander P.R. Milk-alkali syndrome is a major cause of hypercalcaemia among non-end-stage renal disease (non-ESRD) inpatients. Clin Endocrinol (Oxf) 2005, 63:566-576.
9. Yang J.D., Lawson P., Beland S. Severe hypercalcemia from the milk-alkali syndrome. Am J Med 2013, 126:e1-e2.
10. Kallas M., Green F., Hewison M., White C., Kline G. Rare causes of calcitriol-mediated hypercalcemia: a case report and literature review. J Clin Endocrinol Metab 2010, 95:3111-3117.
11. Zhang J.T., Chan C., Kwun S.Y., Benson K.A. A case of severe 1,25-dihydroxyvitamin D-mediated hypercalcemia due to a granulomatous disorder. J Clin Endocrinol Metab 2012, 97:2579-2583.
12. Endres D.B. Investigation of hypercalcemia. Clin Biochem 2012, 45:954-963.
13. Carnevale V., Dionisi S., Nofroni I., Romagnoli E., Paglia F., De Geronimo S., et al. Potential clinical utility of a new IRMA for parathyroid hormone in postmenopausal patients with primary hyperparathyroidism. Clin Chem 2004, 50:626-631.
14. Lee S.H., Kim B.H., Bae M.J., Yi Y.S., Kim W.J., Jeon Y.K., et al. Concurrence of primary hyperparathyroidism and metastatic breast carcinoma affected a parathyroid gland. J Clin Endocrinol Metab 2013, 98:3127-3130.
15. Richey D.S., Welch B.J. Concurrent primary hyperparathyroidism and humoral hypercalcemia of malignancy in a patient with clear cell endometrial cancer. South Med J 2008, 101:1266-1268.
16. Rosner M.A., Dalkin A.C. Onco-nephrology: the pathophysiology and treatment of malignancy-associated hypercalcemia. Clin J Am Soc Nephrol 2012, 7:1722-1729.
17. Clines G.A. Mechanisms and treatment of hypercalcemia of malignancy. Curr Opin Endocrinol Diabetes Obes 2011, 18:339-346.
18. Lumachi F., Brunello A., Roma A., Basso U. Cancer-induced hypercalcemia. Anticancer Res 2009, 29:1551-1556.
19. Basso U., Maruzzo M., Roma A., Camozzi V., Luisetto G., Lumachi F. Malignant hypercalcemia. Curr Med Chem 2011, 18:3462-3467.
20. Clines G.A., Guise T.A. Hypercalcaemia of malignancy and basic research on mechanisms responsible for osteolytic and osteoblastic metastasis to bone. Endocr Relat Cancer 2005, 12:549-583.
21. Fritchie K., Zedek D., Grenache D.G. The clinical utility of parathyroid hormone-related peptide in the assessment of hypercalcemia. Clin Chim Acta 2009, 402:146-149.
22. Wysolmerski J.J. Parathyroid hormone-related protein: an update. J Clin Endocrinol Metab 2012, 97:2947-2956.
23. McCauley L.K., Martin T.J. Twenty-five years of PTHrP progress: from cancer hormone to multifunctional cytokine. J Bone Miner Res 2012, 27:1231-1239.
24. Soki F.N., Park S.I., McCauley L.K. The multifaceted actions of PTHrP in skeletal metastasis. Future Oncol 2012, 8:803-817.
25. Bellon M., Ko N.L., Lee M.J., Yao Y., Waldmann T.A., Trepel J.B., et al. Adult T-cell leukemia cells overexpress Wnt5a and promote osteoclast differentiation. Blood 2013, 121:5045-5054.
26. Demetriou E.T., Pietras S.M., Holick M.F. Hypercalcemia and soft tissue calcification owing to sarcoidosis: the sunlight-cola connection. J Bone Miner Res 2010, 25:1695-1699.
27. Tyler Miller R. Control of renal calcium, phosphate, electrolyte, and water excretion by the calcium-sensing receptor. Best Pract Res Clin Endocrinol Metab 2013, 27:345-358.
28. Hoorn E.J., Zietse R. Disorders of calcium and magnesium balance: a physiology-based approach. Pediatr Nephrol 2013, 28:1195-1206.
29. Loupy A., Ramakrishnan S.K., Wootla B., Chambrey R., delaFaille R., Bourgeois S., et al. PTH-independent regulation of blood calcium concentration by the calcium-sensing receptor. J Clin Invest 2012, 122:3355-3367.
30. Kantham L., Quinn S.J., Egbuna O.I., Baxi K., Butters R., Pang J.L., et al. The calcium-sensing receptor (CaSR) defends against hypercalcemia independently of its regulation of parathyroid hormone secretion. Am J Physiol Endocrinol Metab 2009, 297:E915-E923.
31. Felsenfeld A., Rodriguez M., Levine B. New insights in regulation of calcium homeostasis. Curr Opin Nephrol Hypertens 2013, 22:371-376.
32. Arroyo M., Fenves A.Z., Emmett M. The calcium-alkali syndrome. Proc (Bayl Univ Med Cent) 2013, 26:179-181.
33. Mulder J.E., Bilezikian J.P. Acute management of hypercalcemia. The Parathyroids. Basic and Clinical Concept 2001, 729-743. Academic Press, San DiegoCA. 2nd ed. J.P. Bilezikian, R. Marcus, M.A. Levine (Eds.).
34. Ralston S.H., Coleman R., Fraser W.D., Gallagher S.J., Hosking D.J., Iqbal J.S., et al. Medical management of hypercalcemia. Calcif Tissue Int 2004, 74:1-11.
35. Horwitz M.J., Hodak S.P., Stewart A.F. Non-parathyroid hypercalcemia. An official publication of the American Society for Bone and Mineral Research 2013, 562-571. John Wiley & Sons, Inc, Ames, Iowa. 8th ed. C.J. Rosen (Ed.).
36. Basso S.M.M., Lumachi F., Nascimben F., Luisetto G., Camozzi V. Treatment of acute hypercalcemia. Med Chem 2012, 8:564-568.
37. Carroll M.F., Schade D.S. A practical approach to hypercalcemia. Am Fam Physician 2003, 67:1959-1966.
38. McCurdy M.T., Shanholtz C.B. Oncologic emergencies. Crit Care Med 2012, 40:2212-2222.
39. Carroll R., Matfin G. Endocrine and metabolic emergencies: hypercalcaemia. Ther Adv Endocrinol Metab 2010, 1:225-234.
40. Iacovelli E., Gilio F., Mascia M.L., Scillitani A., Romagnoli E., Pichiorri F., et al. Acute and chronic effects of hypercalcaemia on cortical excitability as studied by 5 Hz repetitive transcranial magnetic stimulation. J Physiol 2011, 589:1619-1626.
41. Frick T.W. The role of calcium in acute pancreatitis. Surgery 2012, 152:S157-S163.
42. Senba M., Kawai K., Mori N. Pathogenesis of metastatic calcification and acute pancreatitis in adult T-cell leukemia under hypercalcemic state. Leuk Res Treatment 2012, 2012. 128617.
43. Chen Y.G., Huang T.Y., Hsieh T.Y., Chen P.J. Acute pancreatitis due to hypercalcemia related to bone metastasis from breast cancer. Q J Med 2013, 106:367-369.
44. Bai H.X., Giefer M., Patel M., Orabi A.I., Husain S.Z. The association of primary hyperparathyroidism with pancreatitis. J Clin Gastroenterol 2012, 46:656-661.
45. El-Sherif N., Turitto G. Electrolyte disorders and arrhythmogenesis. Cardiol J 2011, 18:233-245.
46. Ortega-Carnicer J., Ceres F., Sanabria C. Long QT interval in severe hypercalcaemia. Resuscitation 2004, 61:242-243.
47. Pepe J., Curione M., Morelli S., Colotto M., Varrenti M., Castro C., et al. Arrhythmias in primary hyperparathyroidism evaluated by exercise test. Eur J Clin Invest 2013, 43:208-214.
48. Pepe J., Curione M., Morelli S., Varrenti M., Cammarota C., Cilli M., et al. Parathyroidectomy eliminates arrhythmic risk in primary hyperparathyroidism, as evaluated by exercise test. Eur J Endocrinol 2013, 169:255-261.
49. Garofeanu C.G., Weir M., Rosas-Arellano M.P., Henson G., Garg A.X., Clark W.F., et al. Causes of reversible nephrogenic diabetes insipidus: a systematic review. Am J Kidney Dis 2005, 45:626-637.
50. Khanna A. Acquired nephrogenic diabetes insipidus. Semin Nephrol 2006, 26:244-248.
51. French S., Subauste J., Geraci S. Calcium abnormalities in hospitalized patients. South Med J 2012, 105:231-237.
52. Dionisi S., Minisola S., Pepe J., DeGeronimo S., Paglia F., Memeo L., et al. Concurrent parathyroid adenomas and carcinoma in the setting of multiple endocrine neoplasia type 1: presentation as hypercalcemic crisis. Mayo Clin Proc 2002, 77:866-869.
53. Ziegler R. Hypercalcemic crisis. J Am Soc Nephrol 2001, 12:S3-S9.
54. Beck W., Lew J.I., Solórzano C.C. Hypercalcemic crisis in the era of targeted parathyroidectomy. J Surg Res 2011, 171:404-408.
55. Gasparri C., Camandona M., Mullineris B., Raggio E., Vigna S., Dei Poli M. Acute hyperparathyroidism: our experience with 36 cases. Ann Ital Chir 2004, 75:321-324.
56. Phitayakorn R., McHenry C.R. Hyperparathyroid crisis: use of bisphosphonates as a bridge to parathyroidectomy. J Am Coll Surg 2008, 206:1106-1115.
57. Cannon J., Lew J.I., Solorzano C.C. Parathyroidectomy for hypercalcemic crisis: 40 years' experience and long-term outcomes. Surgery 2010, 148:807-813.
58. Ralston S.H., Gallagher S.J., Patel U., Campbell J., Boyle I.T. Cancer-associated hypercalcemia: morbidity and mortality. Clinical experience in 126 treated patients. Ann Intern Med 1990, 112:499-504.
59. Slomp J., van der Voort P.H., Gerritsen R.T., Berk J.A., Bakker A.J. Albumin-adjusted calcium is not suitable for diagnosis of hyper- and hypocalcemia in the critically ill. Crit Care Med 2003, 31:1389-1393.
60. Stewart A.F. Hypercalcemia associated with cancer. N Engl J Med 2005, 352:373-379.
61. Le Grand S.B., Leskuski D., Zama I. Narrative review: furosemide for hypercalcemia: an unproven yet common practice. Ann Intern Med 2008, 149:259-263.
62. Sargent J.T.S., Smith O.P. Haematological emergencies: managing hypercalcaemia in adults and children with haematological disorders. Br J Haematol 2010, 149:465-477.
63. Hutchison C.A., Batuman V., Behrens J., Bridoux F., Sirac C., Dispenzieri A., et al. The pathogenesis and diagnosis of acute kidney injury in multiple myeloma. Nat Rev Nephrol 2011, 8:43-51.
64. Nancollas G.H., Tang R., Phipps R.J., Henneman Z., Gulde S., Wu W., et al. Novel insights into actions of bisphosphonates on bone: differences in interaction with hydroxyapatite. Bone 2006, 38:617-627.
65. Kimmel D.B. Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical application of nitrogen-containing bisphosphonates. J Dent Res 2007, 86:1022-1033.
66. Russell R.G.G. Bisphosphonates: mode of action and pharmacology. Pediatrics 2007, 119:S150-S162.
67. Russell R.G.G., Watts N.B., Ebetino F.H., Rogers M.J. Mechanisms of action of bisphosphonates: similarities and differences their potential influence on clinical efficacy. Osteoporos Int 2008, 19:733-759.
68. Papapoulos S.E. Bisphosphonates: how do they work?. Best Pract Res Clin Endocrinol Metab 2008, 22:831-847.
69. Drake M.T., Clarke B.L., Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc 2008, 83:1032-1045.
70. Schwartz L.M., Woloshin S. Lost in transmission-FDA information that never reaches clinicians. N Engl J Med 2009, 361:1717-1720.
71. Woloshin S., Schwartz M. FDA drug information that never reaches clinicians. N Engl J Med 2010, 362:563.
72. Major P., Lortholary A., Hon J., Abdi E., Mills G., Menssen H.D., et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized controlled clinical trials. J Clin Oncol 2001, 19:558-567.
73. Onuma E., Azuma Y., Saito H., Tsunenari T., Watanabe T., Hirabayashi M., et al. Increased renal calcium reabsorption by parathyroid hormone related protein is a causative factor in the development of humoral hypercalcemia of malignancy refractory to osteoclastic bone resorption inhibitors. Clin Cancer Res 2005, 11:4198-4203.
74. Bertoldo F., Pancheri S., Zenari S., Boldini S., Giovanazzi B., Zanatta M., et al. Serum 25-hydroxyvitamin D levels modulate the acute-phase response associated with the first nitrogen-containing bisphosphonate infusion. J Bone Miner Res 2010, 25:447-454.
75. Gordon P.L., Frassetto L.A. Management of osteoporosis in CKD stages 3 to 5. Am J Kidney Dis 2010, 55:941-956.
76. Peranzella M.A., Markovitz G.S. Bisphoshonate nephrotoxicity. Kidney Int 2008, 74:1385-1393.
77. Anandaraja A.P. Role of RANKL in bone disease. Trends Endocrinol Metab 2009, 20:88-94.
78. Castellano D., Sepulveda J.M., Garcia-Escobar I., Rodriguez-Antolin A., Sundlöv A., Cortes-Funes H. The role of RANK-Ligand inhibition in cancer: the story of denosumab. Oncologist 2011, 16:136-145.
79. Nakashima T., Hayashi M., Takayanagi H. New insights into osteoclastogenetic signalling mechanisms. Trends Endocrinol Metab 2012, 23:582-590.
80. Stopek A.T., Lipton A., Body J.J., Steger G.G., Tonkin K., de Boer R.H., et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer. A randomized, double-blind study. J Clin Oncol 2010, 28:5132-5139.
81. Henry D.H., Costa L., Goldwasser F., Hirsh V., Hungria V., Pransova J., et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011, 29:1125-1132.
82. Body J.J., Lipton A., Gralow J., Steger G.G., Gao G., Yeh H., et al. Effects of denosumab in patients with bone metastases with or without previous bisphosphonate exposure. J Bone Miner Res 2010, 25:440-446.
83. Boikos S.A., Hammers H.J. Denosumab for the treatment of bisphosphonate-refractory hypercalcemia. J Clin Oncol 2012, 29:e299.
84. Bech A., de Boer H. Denosumab for tumor induced hypercalcemia complicated by renal failure. Ann Intern Med 2012, 156:906-907.
85. Bowyer S.E., White A.M., Ransom D.T., Davidson J.A. Resistant hypercalcemia in metastatic parathyroid carcinoma. Med J Aust 2013, 198:559-561.
86. Warrell R.P., Coonley C.J., Straus D.J., Young C.W. Treatment of patients with advanced malignant lymphoma using gallium nitrate administered as a seven-day continuous infusion. Cancer 1983, 51:1982-1987.
87. Warrell R.P., Bockman R.S., Coonley C.J., Isaacs M., Staszewski H. Gallium nitrate inhibits calcium resorption from bone and is effective treatment for cancer-related hypercalcemia. J Clin Invest 1984, 73:1487-1490.
88. Chitambar C.R. Medical applications and toxicities of gallium compounds. Int J Environ Res Public Health 2010, 7:2337-2361.
89. Bockman R. The effects of gallium nitrate on bone resorption. Semin Oncol 2003, 30(Suppl. 5):5-12.
90. Verron E., Masson M., Khoshniat S., Duplomb L., Wittrant Y., Baud'huin M., et al. Gallium modulates osteoclastic bone resorption in vitro without affecting osteoblasts. Br J Pharmacol 2010, 159:1681-1692.
91. Warrell R.P., Alcock N.W., Bockman R.S. Gallium nitrate inhibits accelerated bone turnover in patients with bone metastases. J Clin Oncol 1987, 5:292-298.
92. McMahan J., Linneman T. A case of resistant hypercalcemia of malignancy with a proposed treatment algorithm. Ann Pharmacother 2009, 43:1532-1538.
93. Warrell R.P., Israel R., Frisone M., Snyder T., Gaynor J.J., Bockman R.S. Gallium nitrate for acute treatment of cancer-related hypercalcemia. A randomized, double-blind comparison to calcitonin. Ann Intern Med 1988, 108:669-674.
94. Cvitkovic F., Armand J.P., Tubiana-Hulin M., Rossi J.F., Warrell R.P. Randomized, double-blind, phase II trial of gallium nitrate compared with pamidronate for acute control of cancer-related hypercalcemia. Cancer J 2006, 12:47-53.
95. Krakoff I.H., Newman R.A., Goldberg R.S. Clinical toxicologic and pharmacologic studies of gallium nitrate. Cancer 1979, 44:1722-1727.
96. Legrand S.B. Modern management of malignant hypercalcemia. Am J Hosp Palliat Care 2011, 28:515-517.
97. Kurahashi I., Matsunuma A., Kawane T., Abe M., Horiuchi N. Dexamethasone enhances vitamin D-24-hydroxylase expression in osteoblastic (UMR-106) and renal (LLC-PK1) cells treated with 1alpha,25-dihydroxyvitamin D3. Endocrine 2002, 17:109-118.
98. Binstock M.L., Mundy G.R. Effect of calcitonin and glucocorticoids in combination on the hypercalcemia of malignancy. Ann Intern Med 1980, 93:269-272.
99. Ozkan B., Hatun S., Bereket A. Vitamin D intoxication. Turk J Pediatr 2012, 54:93-98.
100. Chesnut C.H., Azria M., Silverman S., Engelhardt M., Olson M., Mindeholm L. Salmon calcitonin: a review of current and future therapeutic indications. Osteoporos Int 2008, 19:479-491.
101. Wisneski L.A. Salmon calcitonin in the acute management of hypercalcemia. Calcif Tissue Int 1990, 46(Suppl):S26-S30.
102. Wada S., Yasuda S., Nagai T., Maeda T., Kitahama S., Suda S., et al. Regulation of calcitonin receptor by glucocorticoid in human osteoclast-like cells prepared in vitro using receptor activator of nuclear factor-kappaB ligand and macrophage colony-stimulating factor. Endocrinology 2001, 142:1471-1478.
103. Diskin C.J., Stokes T.J., Dansby L.M., Radcliff L., Carter T.B. Malignancy-related hypercalcemia developing on a bisphosphonate but responding to calcitonin. Clin Lung Cancer 2007, 8:434-435.
104. Pecherstorfer M., Brenner K., Zojer N. Current management strategies for hypercalcemia. Treat Endocrinol 2003, 2:273-292.
105. Thürlimann B., Waldburger R., Senn H.J., Thiébaud D. Plicamycin and pamidronate in symptomatic tumor-related hypercalcemia: a prospective randomized crossover trial. Ann Oncol 1992, 3:619-623.
106. Wang C.C., Chen Y.C., Shiang J.C., Lin S.H., Chu P., Wu C.C. Hypercalcemic crisis successfully treated with prompt calcium-free hemodialysis. Am J Emerg Med 2009, 27. 1174.e1-3.
107. Au S., Dunham M., Godinez T. Treatment of medically refractory hypercalcemic crisis. Int J Artif Organs 2012, 35:538-541.
108. Albright F., Burnett C.H., Cope O., et al. Acute atrophy of bone (osteoporosis) simulating hyperparathyroidism. J Clin Endocrinol 1941, 1:711-716.
109. Cheng C.J., Chou C.H., Lin S.H. An unrecognized cause of recurrent hypercalcemia: immobilization. South Med J 2006, 99:371-374.